6.03

1.79% -0.11

Lantern Pharma Inc (LTRN)

Overview News Price History Option Chain Financials Discussions Forecast

Lantern Pharma Inc stock is currently priced at $6.03, with a 24-hour trading volume of 43,919. It has seen a -1.79% decreased in the last 24 hours and a +0.67% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $6.23 pivot point. If it approaches the $5.97 support level, significant changes may occur.

Previous Close:

$6.14

Open:

$6.11

24h Volume:

43,919

Market Cap:

$64.88M

Revenue:

Net Income/Loss:

$-15.16M

P/E Ratio:

-4.5633

EPS:

-1.3214

Net Cash Flow:

$-13.65M

1W Performance:

-2.11%

1M Performance:

+0.67%

6M Performance:

+49.63%

1Y Performance:

+23.06%

1D Range:

$5.90

$6.33

52W Range:

$2.38

$11.99

Lantern Pharma Inc Stock (LTRN) Company Profile

Name

Lantern Pharma Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

972 277 1136

Address

1920 McKinney Avenue, 7th Floor, Dallas, TX

Employee

Twitter

@lanternpharma

Next Earnings Date

2024-06-13

Latest SEC Filings

LTRN's Discussions on Twitter

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-21	Initiated	H.C. Wainwright	Buy

Lantern Pharma Inc Stock (LTRN) Latest News

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights - Manchestertimes

Manchestertimes

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights - Business Wire

Business Wire

Lantern Pharma (LTRN) Scheduled to Post Quarterly Earnings on Thursday - Defense World

Defense World

Lantern Pharma Inc Stock (LTRN) Financials Data

Lantern Pharma Inc (LTRN) Net Income 2024

LTRN net income (TTM) was -$15.16 million for the quarter ending September 30, 2023, a -5.12% decrease year-over-year.

Lantern Pharma Inc (LTRN) Cash Flow 2024

LTRN recorded a free cash flow (TTM) of -$13.65 million for the quarter ending September 30, 2023, a -12.27% decrease year-over-year.

Lantern Pharma Inc (LTRN) Earnings per Share 2024

LTRN earnings per share (TTM) was -$1.40 for the quarter ending September 30, 2023, a -6.12% decline year-over-year.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.